Molecule targeted therapy for Cholangiocarcinoma based on the gene profiling of cancer stem cell
| Project/Area Number |
19390348
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
NAGINO Masato Nagoya University, 医学系研究科, 教授 (20237564)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOKOYAMA Yukihiro 名古屋大学, 大学院・医学系研究科, 寄附講座講師 (80378091)
KOKURYO Toshio 名古屋大学, 大学院・医学系研究科, 特任助教 (60378023)
安部 哲也 愛知県がんセンター中央病院, 胸部外科部, 医長 (90378092)
|
|---|
| Project Period (FY) |
2007 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000)
Fiscal Year 2010: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2009: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2008: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2007: ¥8,970,000 (Direct Cost: ¥6,900,000、Indirect Cost: ¥2,070,000)
|
|---|
| Keywords | 胆管癌幹細胞 / 分子標的治療 / 肝門部胆管癌 |
|---|
| Research Abstract |
Cancer stem cell, have the ability of differentiation and self-reproduction, is important in carcinogenesis and cancer progression.
We analyzed a gene profiling between CD133 positive HuCCT1 and the CD133 negative HuCCT1 by DNA array. As a result, we were not able to find the relationship between CD133 and hepatic stem cell marker, such as CD45, TER, CD49f, and c-Met.
And then, we inoculated CD133 positive HuCCT1 and the CD133 negative HuCCT1 in the nude mouse. There was significant difference of carcinogenesis in this model. We considered that this caused in various factors, such as the cancer origin, another cancer stem cell marker except CD133.
In addition, we administered Nek2 siRNA in liver metastasis of a nude rat through portal vein using the access port. We recognized decrease of the number of the liver metastasis and the reduction of the tumor volume.
We clarified that the drug delivery system of siRNA through the portal vein was effective.
|
Report
(6 results)
Research Products
(20 results)
